ALK positive

News alerts, weekly reports and conference planners

Entrez ID:

238

Related biomarkers:

‹

›

Related tests:

VENTANA ALK (D5F3) CDx Assay (12)

ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	lorlatinib Sensitive: A1 - Approval lorlatinib Sensitive : A1	lorlatinib Sensitive: A1 - Approval lorlatinib Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	alectinib Sensitive: A1 - Approval alectinib Sensitive : A1	alectinib Sensitive: A1 - Approval alectinib Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
ALK positive	Non-Hodgkin’s Lymphoma	ALK positive	Non-Hodgkin’s Lymphoma	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	ensartinib Sensitive: A1 - Approval ensartinib Sensitive : A1	ensartinib Sensitive: A1 - Approval ensartinib Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	ceritinib Sensitive: A1 - Approval ceritinib Sensitive : A1	ceritinib Sensitive: A1 - Approval ceritinib Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	iruplinalkib Sensitive: A1 - Approval iruplinalkib Sensitive : A1	iruplinalkib Sensitive: A1 - Approval iruplinalkib Sensitive : A1
ALK positive	Non-Hodgkin’s Lymphoma	ALK positive	Non-Hodgkin’s Lymphoma	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2
ALK positive	Peripheral T-cell Lymphoma	ALK positive	Peripheral T-cell Lymphoma	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
ALK positive	Peripheral T-cell Lymphoma	ALK positive	Peripheral T-cell Lymphoma	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	TQ-B3139 Sensitive: B - Late Trials TQ-B3139 Sensitive : B	TQ-B3139 Sensitive: B - Late Trials TQ-B3139 Sensitive : B
ALK positive	T Cell Non-Hodgkin Lymphoma	ALK positive	T Cell Non-Hodgkin Lymphoma	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B
ALK positive	Lung Non-Squamous Non-Small Cell Cancer	ALK positive	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B
ALK positive	Non-Hodgkin’s Lymphoma	ALK positive	Non-Hodgkin’s Lymphoma	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B
ALK positive	Lung Non-Squamous Non-Small Cell Cancer	ALK positive	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B
ALK positive	Lymphoma	ALK positive	Lymphoma	crizotinib Sensitive: B - Late Trials crizotinib Sensitive : B	crizotinib Sensitive: B - Late Trials crizotinib Sensitive : B
ALK positive	Lung Non-Squamous Non-Small Cell Cancer	ALK positive	Lung Non-Squamous Non-Small Cell Cancer	crizotinib Sensitive: B - Late Trials crizotinib Sensitive : B	crizotinib Sensitive: B - Late Trials crizotinib Sensitive : B
ALK positive	Lung Non-Squamous Non-Small Cell Cancer	ALK positive	Lung Non-Squamous Non-Small Cell Cancer	ensartinib Sensitive: C1 - Off-label ensartinib Sensitive : C1	ensartinib Sensitive: C1 - Off-label ensartinib Sensitive : C1
ALK positive	Lung Adenocarcinoma	ALK positive	Lung Adenocarcinoma	lorlatinib Sensitive: C1 - Off-label lorlatinib Sensitive : C1	lorlatinib Sensitive: C1 - Off-label lorlatinib Sensitive : C1
ALK positive	Lung Non-Small Cell Squamous Cancer	ALK positive	Lung Non-Small Cell Squamous Cancer	brigatinib Sensitive: C1 - Off-label brigatinib Sensitive : C1	brigatinib Sensitive: C1 - Off-label brigatinib Sensitive : C1
ALK positive	Neuroendocrine Tumor	ALK positive	Neuroendocrine Tumor	alectinib Sensitive: C1 - Off-label alectinib Sensitive : C1	alectinib Sensitive: C1 - Off-label alectinib Sensitive : C1
ALK positive	Neuroblastoma	ALK positive	Neuroblastoma	lorlatinib Sensitive: C1 - Off-label lorlatinib Sensitive : C1	lorlatinib Sensitive: C1 - Off-label lorlatinib Sensitive : C1
ALK positive	Lung Cancer	ALK positive	Lung Cancer	lorlatinib Sensitive: C1 - Off-label lorlatinib Sensitive : C1	lorlatinib Sensitive: C1 - Off-label lorlatinib Sensitive : C1
ALK positive	Lung Adenocarcinoma	ALK positive	Lung Adenocarcinoma	ceritinib Sensitive: C1 - Off-label ceritinib Sensitive : C1	ceritinib Sensitive: C1 - Off-label ceritinib Sensitive : C1
ALK positive	T Cell Non-Hodgkin Lymphoma	ALK positive	T Cell Non-Hodgkin Lymphoma	crizotinib Sensitive: C1 - Off-label crizotinib Sensitive : C1	crizotinib Sensitive: C1 - Off-label crizotinib Sensitive : C1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	SAF-189 Sensitive: C2 – Inclusion Criteria SAF-189 Sensitive : C2	SAF-189 Sensitive: C2 – Inclusion Criteria SAF-189 Sensitive : C2
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	atezolizumab + alectinib Sensitive: C2 – Inclusion Criteria atezolizumab + alectinib Sensitive : C2	atezolizumab + alectinib Sensitive: C2 – Inclusion Criteria atezolizumab + alectinib Sensitive : C2
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2

ALK positive

Associations